Cullen/Frost Bankers’s Immunocore IMCR Stock Holding History

Cullen/Frost Bankers’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11	Closed	-$1K	–	1149
2022 Q3	$1K	Buy	+11	New	+$524	﹤0.01%	1094

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cullen/Frost Bankers's IMCR Position: Q4 2022 in Review

Cullen/Frost Bankers sold out of Immunocore (IMCR) in Q4 2022, closing a stake of 11 shares — an estimated $1K sold.

Cullen/Frost Bankers first reported a position in IMCR in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 104 funds tracked by Wall St. Rank hold IMCR as of Q4 2022.

Cullen/Frost Bankers reported no remaining Immunocore position as of Q4 2022 after selling out during the quarter.
Cullen/Frost Bankers sold 11 Immunocore shares in Q4 2022, an estimated $1K.
Cullen/Frost Bankers first reported a position in Immunocore in Q3 2022 and held it in 1 quarter.
Cullen/Frost Bankers's Immunocore position peaked at $1K in Q3 2022.
104 funds tracked by Wall St. Rank held Immunocore as of Q4 2022.

Based on Cullen/Frost Bankers's 13F filing for Q4 2022, filed 13 Feb 2023.